Tenosynovial Giant Cell Tumor is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Tenosynovial Giant Cell Tumor have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Tenosynovial Giant Cell Tumor compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tenosynovial Giant Cell Tumor overview

Tenosynovial Giant Cell Tumors are non-cancerous or benign form of tumors arising from the synovium of the joints or in the soft tissues. Genetically caused due to mutations in the stromal cells of synovium and is divided into three different types as Giant cell tumors of the synovium, Giant cell tumors of the tendon sheath, Giant cell tumors of the bursa. It can develop at any part but commonly affected areas are fingers, thumbs, elbow, ankle, and wrist. It is a rare form diagnosed by MRI. Pain, swelling, bump or lump at the site, pain in joints, and stiffness. Surgical removal of the tumor or radiation therapy are treatment steps.

For a complete picture of PTSR and LoA scores for drugs in Tenosynovial Giant Cell Tumor, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.